Moxonidine-LF tablets p/o 0.2mg №10×3

Name:
Moxonidine-LF tablets, covering the surface area of 0.2 mg in a cell. pack No. 10×3
Description:
Round, film-coated tablets, light pink in color, biconvex shape (0.2 mg dosage). The main active ingredient is Moxonidine Release form Film-coated tablets, 0.2 mg. Dosage 0.2 mg Special instructions If it is necessary to cancel simultaneously taken beta-blockers and moxonidine, beta-blockers are first canceled and only after a few days moxonidine. It is not recommended to prescribe tricyclic antidepressants simultaneously with moxonidine. During treatment, regular monitoring of blood pressure, heart rate and ECG is necessary. Stop taking moxonidine should be gradual. Indications for use Arterial hypertension. Dosage and administration Inside, regardless of the meal, drinking plenty of fluids. In most cases, the initial dose of moxonidine is 0.2 mg per day in one dose, preferably in the morning. If the therapeutic effect is insufficient, the dose can be increased after 3 weeks of therapy to 0.4 mg per day for 2 doses or once. The maximum single dose is 0.4 mg. The maximum daily dose, which should be divided into 2 doses, is 0.6 mg. Abrupt discontinuation of moxonidine is not recommended. Moxonidine should be discontinued gradually over 2 weeks. In patients with moderate renal insufficiency (GFR more than 30 ml / min, but less than 60 ml / min), a single dose of moxonidine 0.2 mg and a daily dose of moxonidine 0.4 mg should not be exceeded. In patients on hemodialysis, the initial dose is 0.2 mg per day. If necessary and with good tolerance, the dose can be increased to 0.4 mg per day. Studies on the use of moxonidine in patients with hepatic insufficiency have not been conducted. In elderly patients with normal renal function, dosage recommendations are the same as for adult patients. Use during pregnancy and lactation There are no clinical data on the treatment of pregnant women with moxonidine. Animal studies have shown embryotoxic effects. As a precautionary measure, the use of moxonidine during pregnancy is not recommended. Moxonidine passes into breast milk. Breastfeeding women during the period of treatment are advised to stop breastfeeding or discontinue the drug. Influence on the ability to drive vehicles and control mechanisms During the period of treatment, it is necessary to refrain from driving vehicles and engaging in potentially hazardous activities that require an increased concentration of attention and speed of psychomotor reactions. With caution Parkinson’s disease (severe form), epilepsy, glaucoma, depression, “intermittent” claudication, Raynaud’s disease, atrioventricular block I degree, chronic renal failure (creatinine clearance more than 30, but less than 60), cerebrovascular disease, after myocardial infarction, chronic heart failure I and II class (according to the NYHA classification), patients on hemodialysis; due to lack of application experience – moderate hepatic insufficiency (more than 9 points according to the Child-Pugh classification). Interaction with other drugs Simultaneous use of other antihypertensive drugs enhances the hypotensive effect of moxonidine. Since tricyclic antidepressants may reduce the effect of centrally acting antihypertensive drugs, co-administration of tricyclic antidepressants with moxonidine is not recommended. Moxonidine may enhance the effect of tricyclic antidepressants (simultaneous administration should be avoided), tranquilizers, alcohol, sedatives and hypnotics. Moxonidine is able to moderately improve cognitive impairment in patients receiving lorazepam. The appointment of moxonidine together with benzodiazepines may be accompanied by an increase in the sedative effect of the latter. Moxonidine is excreted by tubular secretion. Interactions with other drugs eliminated by tubular secretion cannot be excluded. With simultaneous oral administration with glibenclamide, the bioavailability of glibenclamide is reduced by 11%. Contraindications Hypersensitivity to the components of the drug; sinus node weakness syndrome, sinoatrial and atrioventricular block II and III degree, severe bradycardia (heart rate (HR) at rest less than 50 bpm), chronic heart failure class III and IV (according to NYHA classification), angioedema in history, severe liver failure, unstable angina pectoris, chronic renal failure (creatinine clearance less than 30 ml / min, creatinine more than 160 μmol / l), age under 18 years (efficacy and safety not established), lactation, pregnancy, concomitant use with tricyclic antidepressants. Hereditary galactose intolerance, lactase deficiency or malabsorption of glucose-galactose. Composition One film-coated tablet contains: active substance: moxonidine – 0.2 mg. excipients: crospovidone, magnesium stearate, lactose monohydrate; for a dosage of 0.2 mg Opadry II pink: polyvinyl alcohol, titanium dioxide (E171), polyethylene glycol, talc, iron oxide red (E172), iron oxide yellow (E172) Overdose Symptoms: headache, sedation, drowsiness, excessive decrease in blood pressure , dizziness, general weakness, bradycardia, dry mouth, vomiting, fatigue and stomach pain. A short-term increase in blood pressure, tachycardia, and hyperglycemia are also potentially possible. Treatment: There is no specific antidote. In the event of a decrease in blood pressure, it is recommended to restore the volume of circulating blood due to the introduction of fluid and the introduction of dopamine. Bradycardia can be treated with atropine. Alpha-adrenergic antagonists may reduce or eliminate paradoxical hypertension in moxonidine overdose. Side effect The frequency of adverse reactions indicated below was determined using the following scale: very often (> 1/10), often (> 1/100 – < 1/10), infrequently (> 1/1000 – < 1/100), unknown (not possible determined based on available data). Especially at the beginning of therapy, the most common adverse reactions were: dry mouth, dizziness, headache, asthenia and drowsiness. The intensity and frequency of side effects decreases with repeated use. From the side of the central nervous system: often - headache, dizziness, drowsiness, distraction, depression of consciousness; infrequently - fainting. From the side of the cardiovascular system: often - vasodilation; infrequently - bradycardia; sometimes - an excessive decrease in blood pressure, orthostatic hypotension, paresthesia of the extremities, peripheral circulation disorders, Raynaud's syndrome. On the part of the organ of hearing and balance: infrequently - tinnitus. From the gastrointestinal tract: very often - dry mouth; often - diarrhea, vomiting, dyspeptic disorders. From the side of the skin and subcutaneous fat: often - skin rash, itching; infrequently - angioedema. From the musculoskeletal system and connective tissue: often - back pain; infrequently - pain in the neck. Mental disorders: often - sleep disturbances, difficulty concentrating; infrequently - irritability. Visual disturbances: sometimes - dryness of the eye, burning sensation of the eye. Endocrine disorders: sometimes - gynecomastia, impotence and decreased libido. General: sometimes - edema of various localization, weakness in the legs, anorexia, pain in the parotid glands. Storage conditions In a place protected from moisture and light at a temperature not exceeding 25 ° C. Keep out of the reach of children. Buy Moxonidine-LF tablets p/o 0.2mg No. 10x3 Price for Moxonidine-LF tablets p/o 0.2mg No. 10x3